2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

3780 Safety and tolerability of bomedemstat in participants with essential thrombocythemia or polycythemia vera who received bomedemstat in a prior clinical study: Updated results from the phase 3 shorespan-017 extension study

Kristen Pettit, MD, David M. Ross, MBBS, PhD2, Andrew Wilson, PhD, MBBS, MSc, BSc, MRCP3, Tara Cochrane, MBBS4, William Stevenson, MBBS, PhD5, James Liang, FRACP, FRCPA, MBChB6, Marco Brociner, MD7, Francesca Palandri, MD, PhD8, Stephen Larsen, PhD, MBBS9, Merit Hanna, MBChB, FRACP, FRCPA10, Alessandro Maria Vannucchi11, Natalia Curto-Garcia, MSc, MD12, Harinder Gill, MBBS, MD13, Uche Okoro14, Jonas S. Samuel Jutzi, PhD15, Uzor Ogbu, PhD, MBBS16, Monia Marchetti, MD17
1 University of Michigan, Ann Arbor, Michigan, United States
2 Royal Adelaide Hospital and SA Pathology, Adelaide, South Australia, Australia
3 University College London Hospitals NHS Foundation Trust, London, United Kingdom
4 Gold Coast University Hospital, Southport, Queensland, Australia
5 Royal North Shore Hospital, University of Sydney, Sydney, New South Wales, Australia
6 Middlemore Clinical Trials, Auckland, New Zealand
7 ASST Sette Laghi Osp di Circolo e Fond Macchi P O Varese, Varese, Italy
8 IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
9 Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, University of Sydney, Sydney, New South Wales, Australia
10 North Shore Hospital, Waitemata District Health Board, Auckland, New Zealand
11 Center of Research and Innovation Myeloproliferative Neoplasms (CRIMM), University Hospital Careggi, University of Florence, Florence, Italy
12 Guy’s and St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London, United Kingdom
13 School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, China
14 Merck & Co., Inc., Rahway, New Jersey, United States
15 Merck & Co., Inc., Rahway, New Jersey, United States
16 Merck & Co., Inc., Rahway, New Jersey, United States
17 Azienda Ospedaliera Universitaria di Alessandria, Alessandria, Italy

Introduction: Essential thrombocythemia (ET), myelofibrosis (MF), and polycythemia vera (PV) are myeloproliferative neoplasms (MPNs) characterized by stem cell–derived clonal myeloproliferation, resulting in thrombotic complications and potential for leukemic transformation. Current management focuses on decreasing symptoms and preventing thrombotic complications; novel therapies that can improve disease course are needed. Bomedemstat is an irreversible inhibitor of lysine-specific demethylase 1, a critical regulator of hematopoiesis, that has shown manageable safety and promising activity in MPNs. Given the chronic disease course of MPNs, long-term evaluation is needed. Shorespan-017 (NCT06351631) is a single-arm, open-label, extension study designed to evaluate long-term safety, tolerability, and efficacy of bomedemstat in participants with MPNs from prior bomedemstat studies. Updated safety data are reported for participants with ET and PV.

Methods: Adult participants with ET, MF, or PV who had transitioned from a bomedemstat study sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, or MSD (feeder study) were included. Participants from the IMG-7289-202/MK-3543-005 study were required to have received ≥6 months of bomedemstat, were safely tolerating treatment, and were continuing to receive clinical benefit per investigator assessment. Participants with ET or PV from studies other than IMG-7289-202/MK-3543-005 must have had confirmed hematologic remission. Participants continued to receive bomedemstat at the dose determined to be safe and efficacious in their feeder study. The primary objective was to evaluate the safety and tolerability of bomedemstat.

Results: Sixty-three participants received treatment with bomedemstat, including 40 with ET, 16 with MF, and 7 with PV. Median time from treatment start on the feeder study to data cutoff (May 1, 2026) was 53.3 months (range, 23.7-67.1). At the time of the data cutoff, 36 participants with ET were ongoing on treatment and 4 discontinued (2 adverse events [AEs], 1 physician decision, 1 progressive disease); 4 participants with PV were ongoing on treatment and 3 discontinued (1 AE, 1 new nonstudy MPN therapy, 1 treatment failure). Median age of participants with ET was 68.5 years (range, 45-88), 17 (43%) were male, and 28 (70%) had an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0. The median age of participants with PV was 74.0 years (range, 61-81), 7 (100%) were male, and 5 (71%) had an ECOG PS score of 0. Among participants with ET, AEs of any grade occurred in 40 participants (100%); the most frequent AEs (≥20%) were diarrhea (33%), contusion (20%), and falls (20%). Treatment-related AEs of any grade occurred in 11 participants (28%) with ET; the most frequent AEs were (≥5%) anemia (8%), contusion (8%), chronic kidney disease (5%), gingival bleeding (5%), and platelet count decreased (5%). Grade 3 or 4 AEs occurred in 21 participants (53%) with ET, most frequently (≥5%) atrial fibrillation (8%), atrial flutter (5%), and pneumonia (5%). Grade 3 or 4 treatment-related AEs occurred in 2 participants with ET (5%; chronic kidney disease, constipation). One participant with ET had a serious treatment-related AE of grade 2 constipation. Two participants (5%) with ET discontinued due to AEs (anemia, treatment-related dysgeusia). Among participants with PV, AEs of any grade occurred in 7 participants (100%); constipation was the only AE to occur in more than 1 participant (43%). Treatment-related AEs occurred in 4 participants (57%) with PV, most of which were grade 1 or 2 in severity. Two participants (29%) had grade 3 or 4 AEs (esophageal hemorrhage, platelet count decreased). One participant (14%) with PV had a grade 3 or 4 treatment-related AE (platelet count decreased). One participant (14%) with PV discontinued treatment due to gastrointestinal hemorrhage that was not considered treatment related. No venous thrombotic events occurred in pts with ET or PV. No participants with ET or PV died due to AEs.

Conclusion: In this updated analysis, long-term treatment with bomedemstat continued to demonstrate manageable safety in participants who remained on therapy after prior clinical study participation. Late-emerging toxicities were uncommon and no venous thrombotic events occurred. These findings support ongoing evaluation of bomedemstat as a long‑term treatment option in MPNs.

Kristen Pettit, MD: Takeda - Research Funding; AJAX - Research Funding; AbbVie - Research Funding; Blueprint - Research Funding; Kartos - Research Funding; Incyte - Research Funding; Janssen - Research Funding; Merck - Research Funding; Kura - Research Funding; GSK - Research Funding; PharmaEssentia - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony)